Symvivo is a clinical-stage gene therapy company developing oral DNA vaccines for life threatening diseases, such as COVID-19, with broader therapeutic potential for IV therapeutics in cancer and genetic diseases. Our current programs in the clinical and preclinical space span oncology, ischemic heart disease, vaccines and rare diseases.
Alexander Graves is the founder and CEO of Symvivo Corporation. He holds an Honours in Biomedical Sciences specializing in Biochemistry (H.BmSc) from the University of Western Ontario, as well as MBA from the University of British Columbia. Alexander was recognized in the Top 30 Under 30 by BC Business Magazine for his work with Symvivo, and is a graduate of the Center for Drug Research and Developments Biotechnology Executive Training Program, a nationally competitive program for Canada’s top executives in the life sciences.
Lloyd Mackenzie has over 25 years’ experience in the biopharmaceutical industry with expertise in chemistry, manufacturing, medicinal chemistry, and biochemistry. Mr. Mackenzie was previously the Chief Development Officer at NervGen Pharma and prior to that he was Chief Development Officer at Notable Labs, a precision oncology platform company. He has held senior management positions with Aquinox Pharmaceuticals, the most recent being Chief Operating Officer, where he oversaw R&D operations including preclinical, manufacturing, and clinical operations. Mr. Mackenzie holds a BSc. in Chemistry and Biochemistry from Simon Fraser University.
Sheetal leads the preclinical therapeutic R&D program at Symvivo Corporation and brings extensive preclinical drug development experience to Symvivo across a broad range of indications. He was formerly in the Medicinal Chemistry group at viDA Therapeutics Inc. as a senior scientist, where he contributed to the design and optimization of first-in-class chemical inhibitors of extracellular proteases to treat autoimmune and chronic inflammation. He trained as a postdoctoral fellow at the Centre for Drug Research and Development contributing to the translation of validation of health-related research in Canada. Sheetal earned his Ph.D. in biochemistry from the University of Alberta, and subsequently conducted postdoctoral research in gene expression and cellular development at the University of British Columbia.
Dr. Sievers brings more than 25 years experience in the biotechnology industry and academia. His expertise spans across multiple cancer indications including acute myeloid leukemia, myelodysplastic syndromes, Hodgkin and non-Hodgkin lymphoma, melanoma, and renal cell carcinoma. He is an accomplished educator, guest speaker, and strategist, with deep understanding of trial design, experimental medicine, and both early and late stages of clinical development. Dr. Sievers most recently served as Senior Vice President, Clinical Development at Seattle Genetics, where he also held several other senior clinical leadership positions over the past nine years. Notably, during his tenure at Seattle Genetics he played a key role in the development and approval of ADCETRIS®. Dr. Sievers started his industry career as Medical Director at ZymoGenetics. Prior to joining the biotechnology industry, Dr. Sievers spent over a decade at the Fred Hutchinson Cancer Research Center practicing medicine in the areas of hematology and oncology. He received his Medical and Bachelor of Arts degrees from Brown University.
Hamish Clark leads the Finance and Administration department at Symvivo and has held senior roles in private equity firms in the UK. Prior to joining Symvivo, Hamish was the Director of Finance at a major law firm. Hamish was awarded his B.Com (accounting) from the University of Canterbury and his CA from the Chartered Accountants Australia & New Zealand. Hamish also has his CPA from the Chartered Professional Accountants of British Columbia.
Patrick is responsible for the process development manufacturing and quality at Symvivo. Dr. Gearing has extensive development and manufacturing experience and over 25 years of experience in the biotechnology industry and has contributed to the commercialization of several products including Bexxar, Adcetris and Tepezza. He owns and operates Ridge Biotechnology Consulting, LLC and has operated as an independent consultant for over 15 years. Dr. Gearing was awarded his PhD. in organic chemistry from Heriot-Watt University (Edinburgh, U.K)
Michelle Jones is a registered nurse with nearly 20 years of experience in biotechnology and pharmaceutical research. She has made significant contributions to advancing the development programs in both industry (Bold Therapeutics, Qu Biologics, Protiva Biotherapeutics) and academic settings (CIHR Canadian HIV Trials Network, University of British Columbia). Michelle has led teams in developing new drugs and biologics across all phases of the clinical trial spectrum, specializing in clinical operations oversight, strategic initiatives, business development and corporate planning. Michelle’s clinical experience spans multiple indications, including oncology, infectious diseases (HIV, Hepatitis B & C), IBD and dermatology. She holds a B.Sc. in Biochemistry (SFU), a Master’s degree in Nursing (McGill) and an MBA (Management of Biotechnology specialization) (SFU).